Opioids for Chronic Pain: What UK Guidelines Actually Say in 2026

If you live with long-term pain in the UK, you’ve probably heard some version of this line from a GP: “We don’t really prescribe opioids for that anymore.” It can feel abrupt, even dismissive, especially if you’ve been managing pain for years and just want relief. But the shift isn’t a passing trend or a cost-cutting measure  it’s the result of a deliberate, evidence-based change in national guidance that reshaped how chronic pain is treated across England, and influenced practice throughout the rest of the UK.

This guide breaks down what the guidelines actually say, where opioids still have a role, and what to expect if you’re starting a conversation about pain management with your doctor in 2026.

The Short Answer

For chronic primary pain  pain that isn’t fully explained by an underlying condition, such as fibromyalgia or non-specific widespread pain 

UK guidance advises against starting opioids at all. For chronic secondary pain, where there’s an identifiable cause like osteoarthritis or nerve damage, opioids aren’t ruled out, but they’re treated as a limited, closely monitored option rather than a default.

That distinction between primary and secondary pain is the single most important thing to understand, because it determines almost everything else in how a clinician will approach your case.

The Guideline Behind the Shift: NICE NG193

The foundation of current UK practice is a National Institute for Health and Care Excellence guideline published in 2021, known as NG193, covering the assessment and management of chronic pain in adults and young people aged 16 and over. It remains the operative guidance in 2026, and it marked a genuine departure from how chronic pain had been treated for the previous two decades.

Before NG193, opioids were widely prescribed for long-term pain of almost any kind, often following a “step up the ladder” approach borrowed from cancer pain management. NG193 broke from that model. The committee behind it reviewed the evidence on medicines commonly used for chronic primary pain, including opioids, gabapentinoids, benzodiazepines and antipsychotics, and concluded that the evidence for meaningful, lasting benefit was weak, while the evidence of harm from longer-term use was solid enough to act on.

The guideline draws a firm line: for chronic primary pain, clinicians are advised not to start opioid treatment, because the risk of dependence and other harms outweighs any demonstrated benefit for this specific pain category.

Why Chronic Primary Pain Is Treated Differently

Chronic primary pain is classified as a condition in its own right rather than a symptom of something else. Conditions like fibromyalgia, chronic widespread pain and some forms of chronic pelvic pain fall into this category. Because there’s no single tissue-level cause to target, medication that works by blocking a specific pain pathway tends to underperform  and NICE’s evidence review reflected that.

Instead, NG193 points toward a different toolkit for chronic primary pain:

• Supervised group exercise programmes
• Psychological therapies, particularly acceptance and commitment therapy (ACT) or cognitive behavioural therapy (CBT)
• Acupuncture, considered within a defined course
• In some cases, a single antidepressant (such as an SNRI), which may help with sleep and quality of life even without a diagnosis of depression

The guideline is also explicit about what should not be started for chronic primary pain: antiepileptic drugs including gabapentinoids, antipsychotics, benzodiazepines, ketamine and corticosteroid trigger point injections, alongside opioids.

What Changes for Chronic Secondary Pain

Chronic secondary pain  arising from a known condition such as rheumatoid arthritis, endometriosis, or nerve damage  isn’t governed by the same blanket restriction. Here, management follows the NICE guidance relevant to the specific condition, and opioids can still be considered as part of a broader plan. But even in this category, the direction of travel is caution: opioids are positioned as one option among several, not a first-line treatment, and the same monitoring principles apply.

A person can also have a mix of both pain types at once, which is common in practice. In these cases, clinicians are expected to use judgement about which elements of the pain are being driven by an identifiable condition and which are better understood as primary pain in their own right.

The Companion Guideline: Safe Prescribing and Withdrawal (NG215)

A second NICE guideline, NG215, sits alongside NG193 and governs how opioids, benzodiazepines, gabapentinoids, Z-drugs and antidepressants should be prescribed and, where necessary, tapered. It applies across both primary and secondary care and sets out the expectation that:

• Anyone starting one of these medicines should have an open discussion about the risk of dependence and withdrawal before treatment begins
• People already taking these medicines long-term should have regular medication reviews
• If a medicine isn’t providing clear benefit, or the harms are starting to outweigh the benefit, there should be a shared, structured plan to reduce and stop it  not an abrupt withdrawal

This guideline is a large part of why long-term opioid patients in the UK are increasingly being invited in for medication reviews, even if their prescription has stayed stable for years. It isn’t about punishing patients; it’s a structural response to the recognised risk that opioid use beyond around six months is associated with a meaningfully higher risk of dependence. Buy Xanax Online UK

What About the “Two to Four Week” Rule?

One detail that surprises a lot of patients: several UK prescribing resources, drawing on guidance from the Faculty of Pain Medicine’s Opioids Aware resource, note that people who don’t get useful pain relief from opioids within two to four weeks of starting them are unlikely to benefit from continuing. In practice, this means that if opioids aren’t clearly working early on, the expectation is that they should be stopped rather than escalated  even if there’s no other treatment readily available to replace them.

This is a shift away from the older assumption that a higher dose is always worth trying next. It also explains why some patients are told to come off opioids even when they still report pain: if the medicine isn’t demonstrably reducing that pain, continuing it is considered to carry risk without proportionate benefit.

What This Means for Specific Conditions

• Low back pain and sciatica: Guidance is now firm that opioids should not be offered for low back pain, and weak opioids are reserved for acute pain only where anti-inflammatory drugs are contraindicated.
• Fibromyalgia and widespread pain: Falls squarely under chronic primary pain rules  opioids are not recommended as a starting treatment.
• Osteoarthritis and inflammatory arthritis: Treated as secondary pain; opioids may be considered but sit within condition-specific NICE guidance and are not first-line.
• Neuropathic pain: Managed under separate NICE guidance for neuropathic pain, with opioids again positioned as a later option rather than an initial one. Online Pharmacy UK 

What to Expect at Your GP Appointment

If you’re bringing up chronic pain with a GP or pain clinic in 2026, the conversation is likely to look different from a decade ago. Expect:

1. A biopsychosocial assessment  questions not just about pain intensity, but sleep, mood, activity levels and how pain is affecting daily function.
2. A clear distinction being drawn between whether your pain is being treated as primary, secondary, or a mix of both.
3. Non-drug options offered first, particularly for primary pain  this might feel frustrating if you’ve already tried physiotherapy or exercise programmes, so it’s worth being specific about what you’ve already attempted.
4. A time-limited trial if opioids are started, with an explicit review point, usually within a few weeks, to assess whether they’re actually helping.
5. Regular medication reviews if you’re already on long-term opioids, with a shared conversation about tapering if the benefit isn’t clear. How can i order Opion medications in UK 

A Note on Patient Experience

It’s worth being honest that this shift has been genuinely difficult for some patients, particularly those who had been stable on long-term opioids for years before NG193 and NG215 changed local prescribing practice. Patient advocacy groups and some clinicians have raised concerns that the guidance can be applied too rigidly, leading to rapid tapering for people who felt their opioids were working well with few side effects.

NICE’s own guidance anticipates this: it states that where someone is on a stable, low dose with clear benefit and minimal harm, the priority should be a shared plan to continue safely  not automatic withdrawal. If a taper is being proposed, it’s reasonable to ask your prescriber to talk through the evidence for your specific situation rather than a blanket policy.

Key Takeaways

• UK opioid guidance for chronic pain is driven primarily by NICE guideline NG193 (2021), still current in 2026, alongside NG215 on safe prescribing and withdrawal.
• Opioids are not recommended for chronic primary pain, including conditions like fibromyalgia.
• For chronic secondary pain, opioids remain an option but are not first-line and are subject to condition-specific NICE guidance.
• A trial of opioids should show a clear benefit within two to four weeks, or the expectation is to stop rather than increase the dose.
• Long-term opioid users should expect regular reviews, but stable, low-dose use with genuine benefit isn’t meant to be withdrawn automatically.

Frequently Asked Questions

Is it true GPs can’t prescribe opioids for chronic pain in the UK anymore? No GPs can still prescribe opioids, but current guidance advises against starting them for chronic primary pain specifically, and treats them as a limited, closely reviewed option for chronic secondary pain.

Does this guidance apply in Scotland, Wales and Northern Ireland? NICE guidelines formally cover England. Scotland, Wales and Northern Ireland have their own health bodies and may adapt or reference NICE guidance differently, though NG193’s principles have broadly influenced practice across the UK.

What if I’ve been on opioids for years and they’re working for me? Current guidance supports continuing treatment where there’s clear benefit and manageable harm, agreed through a shared decision with your prescriber, rather than automatic tapering.

Are there alternatives that actually work for chronic primary pain? Supervised exercise programmes and psychological therapies such as ACT or CBT have the strongest evidence base in current NICE guidance, alongside a possible trial of a single antidepressant for some patients.